Skip to main content

Table 2 SHI annual expenditure for pharmacologically-treated patients with diabetes, 2010

From: The burden and treatment of diabetes in France

  

Total cost (€ billions)

Screening

0.03

Treatment/prevention of complications

2.5

 Glycemic control

1.7

 

 Screening of complications

0.1

 

 Prevention of cardiovascular complications

0.8

 

Treatment of diabetes-related complications

4.2

 Cardiovascular

0.8

 

 Renal insufficiency

0.7

 

 Neuropathy

0.3

 

 Vision loss

0.1

 

 Other complications

0.3

 

Health expenditure indirectly related to diabetes*

3.6

Health expenditure unrelated to diabetes**

7.4

Total health expenditure for patients with treated diabetes

17.7

  1. *Expenditure related to pathologies frequently found in patients with diabetes (e.g., certain cancers, obesity).
  2. **Expenditure for patients with diabetes a priori unrelated to diabetes, including the share of the cost of complications not attribuk to diabetes, as well as other health expenditures for these patients that are not diabetes-related.
  3. Source: CNAMTS [41].